Literature DB >> 19182676

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Benjamin J Park1, Kathleen A Wannemuehler, Barbara J Marston, Nelesh Govender, Peter G Pappas, Tom M Chiller.   

Abstract

OBJECTIVE: Cryptococcal meningitis is one of the most important HIV-related opportunistic infections, especially in the developing world. In order to help develop global strategies and priorities for prevention and treatment, it is important to estimate the burden of cryptococcal meningitis.
DESIGN: Global burden of disease estimation using published studies.
METHODS: We used the median incidence rate of available studies in a geographic region to estimate the region-specific cryptococcal meningitis incidence; this was multiplied by the 2007 United Nations Programme on HIV/AIDS HIV population estimate for each region to estimate cryptococcal meningitis cases. To estimate deaths, we assumed a 9% 3-month case-fatality rate among high-income regions, a 55% rate among low-income and middle-income regions, and a 70% rate in sub-Saharan Africa, based on studies published in these areas and expert opinion.
RESULTS: Published incidence ranged from 0.04 to 12% per year among persons with HIV. Sub-Saharan Africa had the highest yearly burden estimate (median incidence 3.2%, 720 000 cases; range, 144 000-1.3 million). Median incidence was lowest in Western and Central Europe and Oceania (</=0.1% each). Globally, approximately 957 900 cases (range, 371 700-1 544 000) of cryptococcal meningitis occur each year, resulting in 624 700 deaths (range, 125 000-1 124 900) by 3 months after infection.
CONCLUSION: This study, the first attempt to estimate the global burden of cryptococcal meningitis, finds the number of cases and deaths to be very high, with most occurring in sub-Saharan Africa. Further work is needed to better define the scope of the problem and track the epidemiology of this infection, in order to prioritize prevention, diagnosis, and treatment strategies.

Entities:  

Mesh:

Year:  2009        PMID: 19182676     DOI: 10.1097/QAD.0b013e328322ffac

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  965 in total

1.  Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells.

Authors:  Lilit Aslanyan; Hiu H Lee; Vaibhav V Ekhar; Raddy L Ramos; Luis R Martinez
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Clinical characteristics and prognosis of pediatric cryptococcosis in Beijing Children's Hospital, 2002-2014.

Authors:  Linlin Liu; Lingyun Guo; Yue Liu; Tianming Chen; Shaoying Li; Yonghong Yang; Gang Liu
Journal:  Eur J Pediatr       Date:  2017-08-03       Impact factor: 3.183

3.  Sterylglucoside catabolism in Cryptococcus neoformans with endoglycoceramidase-related protein 2 (EGCrP2), the first steryl-β-glucosidase identified in fungi.

Authors:  Takashi Watanabe; Tomoharu Ito; Hatsumi M Goda; Yohei Ishibashi; Tomofumi Miyamoto; Kazutaka Ikeda; Ryo Taguchi; Nozomu Okino; Makoto Ito
Journal:  J Biol Chem       Date:  2014-10-31       Impact factor: 5.157

Review 4.  Adaptation of Cryptococcus neoformans to mammalian hosts: integrated regulation of metabolism and virulence.

Authors:  Jim Kronstad; Sanjay Saikia; Erik David Nielson; Matthias Kretschmer; Wonhee Jung; Guanggan Hu; Jennifer M H Geddes; Emma J Griffiths; Jaehyuk Choi; Brigitte Cadieux; Mélissa Caza; Rodgoun Attarian
Journal:  Eukaryot Cell       Date:  2011-12-02

Review 5.  Management of cryptococcal meningitis in sub-saharan Africa.

Authors:  Arthur Jackson; Mina C Hosseinipour
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

6.  Phosphatidylserine synthesis is essential for viability of the human fungal pathogen Cryptococcus neoformans.

Authors:  Paulina Konarzewska; Yina Wang; Gil-Soo Han; Kwok Jian Goh; Yong-Gui Gao; George M Carman; Chaoyang Xue
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

7.  Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production.

Authors:  Benjamin J Murdock; Gary B Huffnagle; Michal A Olszewski; John J Osterholzer
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

Review 8.  Vaccine immunity against fungal infections.

Authors:  Som G Nanjappa; Bruce S Klein
Journal:  Curr Opin Immunol       Date:  2014-03-03       Impact factor: 7.486

9.  Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly.

Authors:  Pardeep Kumar; Christian Heiss; Felipe H Santiago-Tirado; Ian Black; Parastoo Azadi; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2014-02-28

10.  Identification of cyclosporin C from Amphichorda felina using a Cryptococcus neoformans differential temperature sensitivity assay.

Authors:  Lijian Xu; Yan Li; John B Biggins; Brian R Bowman; Gregory L Verdine; James B Gloer; J Andrew Alspaugh; Gerald F Bills
Journal:  Appl Microbiol Biotechnol       Date:  2018-02-02       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.